In an adult with chronic prurigo nodularis refractory to high‑potency topical corticosteroids, intralesional steroids, antihistamines, moisturizers, and phototherapy, how should methotrexate be used (initial dose, titration, folic acid supplementation, laboratory monitoring, contraindications) and what alternative systemic therapies are available?

Methotrexate for Refractory Prurigo Nodularis

Methotrexate is an effective systemic treatment option for chronic prurigo nodularis refractory to conventional therapies, with 89-94% of patients achieving objective improvement at 6-12 months when dosed at 7.5-25 mg weekly with concurrent folic acid supplementation. 1, 2

Evidence Base for Methotrexate in Prurigo Nodularis

While methotrexate lacks FDA approval specifically for prurigo nodularis, retrospective studies demonstrate substantial efficacy:

• A multicentre study of 39 patients showed 94% overall response rate at 6 months (56% complete remission) with median weekly dose of 15 mg 2
• Mean time to objective improvement was 2.4 months, with mean response duration of 19 months 2
• A separate series of 13 elderly patients (mean age 75.8 years) showed remission or marked improvement (>75% reduction in pruritus and lesion severity) in 77% of cases 1
• Systematic review evidence rates methotrexate as level 4 evidence but demonstrates clinical benefit 3

Methotrexate Dosing Protocol

Initial dose: Start at 7.5-10 mg once weekly as a single dose 4

Titration schedule:

• Increase by 2.5-5 mg increments every 2-4 weeks based on response and tolerability 4
• Target maintenance dose: 15-25 mg weekly for most patients 4, 1, 2
• Maximum dose should not exceed 25 mg weekly 4
• Average time to maximum effect is 10 weeks; minimal additional benefit occurs after 12-16 weeks of dose escalation 4

Route of administration:

• Oral tablets are preferred by patients but have lower bioavailability 4
• Subcutaneous or intramuscular injection provides superior bioavailability and reduces gastrointestinal side effects 4, 1
• 0.1 mL of 25 mg/mL injection solution equals one 2.5 mg oral tablet for straightforward conversion 4

Alternative dosing: Divided dosing (three doses over 24 hours, given every 12 hours) may be used but requires appropriate dose adjustment 4

Folic Acid Supplementation

Folic acid or folinic acid supplementation is mandatory to reduce gastrointestinal and hepatic adverse effects. 4

• Standard recommendation: 1-5 mg folic acid daily or 5 mg once weekly (taken on a different day than methotrexate) 4
• Critical caveat: Excessive folic acid doses may reduce methotrexate efficacy, so avoid doses >5 mg daily unless clinically necessary 4

Laboratory Monitoring Protocol

Baseline testing (before first dose):

• Complete blood count (CBC) with differential 4, 5
• Comprehensive metabolic panel including liver function tests (AST, ALT, alkaline phosphatase, bilirubin) 4
• Serum creatinine and estimated glomerular filtration rate 4
• Hepatitis B and C serologies 4
• Pregnancy test for women of childbearing potential 4

Early monitoring:

• Repeat CBC 5-6 days after the first dose to detect early myelosuppression 4, 5
• Weekly CBC and liver function tests for the first month 4

Ongoing monitoring (stable patients):

• CBC and liver function tests every 3-6 months assuming normal results 4
• For persistent laboratory abnormalities, repeat testing in 2-4 weeks and consider gastroenterology/hepatology referral 4

Hepatotoxicity surveillance:

• Baseline noninvasive hepatic fibrosis assessment (e.g., FIB-4 index, APRI score, or vibration-controlled transient elastography) for patients with risk factors: obesity, diabetes, history of alcohol use, chronic hepatitis 4
• Annual hepatic fibrosis screening if methotrexate is continued despite baseline abnormalities 4
• Liver biopsy is no longer routinely recommended but may be considered if persistent transaminase elevations occur 4

Absolute Contraindications

Methotrexate must not be used in the following circumstances:

• Pregnancy or breastfeeding 4, 5
• Men or women attempting conception (discontinue ≥3 months before attempting pregnancy) 4
• Cirrhosis or significant hepatic damage 4
• Severe anemia, leukopenia, or thrombocytopenia 4
• Significant renal impairment (adjust dose or avoid if eGFR <30 mL/min) 4

Relative Contraindications and Precautions

• Active infection or immunodeficiency 4
• Chronic alcohol use (>1 drink/day for women, >2 drinks/day for men) 4
• Obesity and diabetes (increased hepatotoxicity risk) 4
• Concomitant use of nephrotoxic drugs, NSAIDs, sulfonamides, or trimethoprim (increases methotrexate toxicity) 4

Mandatory contraception: All women of childbearing potential and men must use reliable contraception during treatment and for ≥3 months after discontinuation 4, 5

Common Adverse Effects and Management

Gastrointestinal symptoms (nausea, anorexia):

• Most common side effect; often improves with parenteral administration 4
• Ensure adequate folic acid supplementation 4

Myelosuppression:

• Monitor CBC regularly; dose-dependent and reversible 4
• Higher risk with renal impairment or drug interactions 4

Hepatotoxicity:

• Risk increases with cumulative dose, obesity, diabetes, and alcohol use 4
• Long-term fibrosis/cirrhosis risk is related to total cumulative dose 4

Rare but serious:

• Pneumonitis (rare; presents with cough, dyspnea, fever) 4, 2
• Requires immediate discontinuation and pulmonary evaluation 4

When to Discontinue or Switch Therapy

• Failure to respond: If no improvement after 12-16 weeks on adequate dose (≥15 mg weekly), consider discontinuation 4
• Sustained remission: Once near-clearance is achieved and maintained, taper or discontinue methotrexate and maintain with topical therapies 4
• Adverse effects: Discontinue for persistent laboratory abnormalities, pneumonitis, or intolerable side effects 4, 2

Alternative Systemic Therapies for Refractory Prurigo Nodularis

When methotrexate is contraindicated, ineffective, or not tolerated, consider the following alternatives in order of preference:

First-Line Alternatives (Strongest Evidence)

Dupilumab (IL-4/IL-13 inhibitor):

• FDA-approved for prurigo nodularis in 2022 4, 6
• Dosing: 600 mg subcutaneous loading dose, then 300 mg every 2 weeks 6
• Excellent safety profile with >5 years clinical experience 6
• No laboratory monitoring required 6
• Most common adverse effect: conjunctivitis (6-15% in trials, 4.2% discontinuation rate) 6

JAK inhibitors (upadacitinib, abrocitinib, baricitinib):

• Strong recommendations for severe refractory disease 4, 6
• Faster onset of action than dupilumab 6
• FDA boxed warnings: Increased risk of serious cardiovascular events, malignancy, thrombosis, and death (based on tofacitinib data in RA patients ≥50 years with CV risk factors) 6
• Should be reserved for patients who fail or cannot use biologics 6

Second-Line Alternatives

Cyclosporine:

• Dosing: 3-6 mg/kg/day divided into two doses 5, 7, 8
• Clinical response typically within 3 weeks 5, 7
• Limit duration to 3-4 months due to nephrotoxicity and hypertension risk 5, 7
• Contraindications: abnormal renal function, uncontrolled hypertension, current/past malignancy 5, 7
• Monitoring: baseline and periodic serum creatinine and blood pressure; reduce dose by 1 mg/kg/day if creatinine rises >25% above baseline 5, 7
• Retrospective data shows 38% significant improvement in prurigo nodularis at 16 weeks 8

Azathioprine:

• Dosing: 1-3 mg/kg/day 5, 7
• Clinical response within 4 weeks 5, 7
• Consider TPMT enzyme testing to guide dosing and predict toxicity risk 4, 7
• Contraindications: pregnancy, breastfeeding, severe anemia, significant hepatic injury 5, 7
• Monitoring: baseline CBC, creatinine, electrolytes; ongoing CBC and liver function tests 5, 7

Mycophenolate mofetil:

• Dosing: 1-4 mg/kg/day 5
• Conditional recommendation; variably effective 4, 5
• Consider when first- and second-line agents are unsuitable 5

Phototherapy

Narrowband UVB:

• Conditional recommendation for atopic dermatitis and pruritic conditions 4
• Retrospective data shows 35% significant improvement in prurigo nodularis at 16 weeks 8
• High relapse risk after discontinuation 9
• Requires 2-3 treatments weekly for several months 9

Therapies to Avoid

Systemic corticosteroids:

• Conditional recommendation AGAINST use for chronic management 4, 7, 6
• Reserve exclusively for acute severe flares as short-term bridge therapy (days to weeks) 5, 7, 6
• Substantial risk of serious adverse events and rebound flares upon discontinuation 4, 6

Clinical Algorithm for Treatment Selection

1. First attempt: Optimize topical therapies (high-potency corticosteroids, intralesional triamcinolone), antihistamines, and phototherapy 9, 3

2. If refractory and FDA-approved agents accessible: Dupilumab is preferred first-line systemic therapy 4, 6

3. If dupilumab contraindicated/unavailable or faster onset needed: Consider JAK inhibitors (if age <50 or no CV risk factors) 6

4. If biologics/JAK inhibitors inaccessible or contraindicated: Methotrexate 7.5-25 mg weekly with folic acid supplementation 1, 2

5. If methotrexate contraindicated: Cyclosporine 3-6 mg/kg/day for short-term control (≤4 months), then transition to alternative agent 5, 7, 8

6. If cyclosporine contraindicated: Azathioprine 1-3 mg/kg/day (consider TPMT testing) 5, 7

7. Adjunctive measures throughout: Continue aggressive emollient therapy (≥twice daily) and optimize topical anti-inflammatory agents to minimize systemic medication requirements 5